infd_a_1544423_sm3488.tiff (28.55 MB)View fileThis item contains files with download restrictions
IMAGE
infd_a_1544423_sm3487.tiff (28.55 MB)View fileThis item contains files with download restrictions
DOCUMENT
infd_a_1544423_sm3375.doc (80.5 kB)View fileThis item contains files with download restrictions
DOCUMENT
infd_a_1544423_sm3367.doc (29.5 kB)View fileThis item contains files with download restrictions
Next page
Previous page
1/1
Switch ViewSwitch between different file views
Thumbnail viewList viewFile view
5 filesFullscreen
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort
posted on 2019-04-10, 07:02authored byD. F. Bavaro, D. Di Carlo, P. Zuccalà, F. Bai, F. Incardona, A. Battisti, S. Giachè, E. Salomoni, R. Gagliardini, S. Di Giambenedetto, M. Pecorari, M. Zazzi, A. De Luca, A. Bezenchek, S. Lo Caputo
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients – evidence from a large observational cohort
Funding
This study has been funded within the ARCA Mentor School by unconditional educational grants from: ViiV Healthcare, GILEAD Sciences, Janssen-Cilag, Hologic, Merck Sharp and Dohme, Bristol-Myers Squibb, Siemens Healthineers